Weekly combination of oxaliplatin (OX) and irinotecan (IRI) in 5-FU resistant colorectal cancer (CRC)
Albrecht Kretzschmar(Roche (Switzerland)), Peter Reichardt(Helios Hospital Berlin-Buch), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Daniel Pink(Universitätsmedizin Greifswald), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), B. Dörken, Helmut Oettle, Claus Jürgen Scholz(University of Würzburg), Axel Grothey(Campbell Clinic)
Cited by 4
Related Papers
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k